Hepion Pharmaceuticals (HEPA) News Today → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free HEPA Stock Alerts $1.32 -0.17 (-11.41%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?finance.yahoo.com - April 22 at 4:41 PMWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?investorplace.com - April 22 at 9:09 AMWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?investorplace.com - April 22 at 8:56 AMHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trialstockhouse.com - April 21 at 3:48 PMHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trialfinanznachrichten.de - April 20 at 7:53 AMHepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource Constraintsmarketwatch.com - April 19 at 8:33 PMHepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down Trialmarketwatch.com - April 19 at 8:33 PMHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trialfinance.yahoo.com - April 19 at 8:33 PMmarketbeat.com - April 19 at 4:32 PMHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trialglobenewswire.com - April 19 at 4:30 PMHEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023msn.com - April 17 at 12:39 AMShort Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Expands By 11.0%americanbankingnews.com - April 15 at 6:42 AMHepion Pharmaceuticals Inc HEPAmorningstar.com - April 14 at 6:46 PMHepion Pharmaceuticals Inc (HEPA)investing.com - March 24 at 2:04 AMHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcellglobenewswire.com - March 6 at 8:30 AMHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceedsfinance.yahoo.com - February 16 at 10:34 AMHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceedsglobenewswire.com - February 16 at 8:00 AMHepion Pharmaceuticals to Present at NASH-TAG 2024finance.yahoo.com - January 3 at 6:40 PMHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changesfinanznachrichten.de - December 7 at 2:59 PMHepion Pharmaceuticals downgraded to Hold from Buy at Brooklinerealmoney.thestreet.com - December 7 at 2:59 PMHepion Sets Restructuring; To Explore Strategic Optionsmarketwatch.com - December 7 at 9:59 AMHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changesfinance.yahoo.com - December 7 at 9:59 AMmarketbeat.com - December 7 at 7:58 AMHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summitfinance.yahoo.com - November 28 at 4:19 PMHepion Pharmaceuticals says Wijngaard buys 5K shares in comsn.com - November 28 at 3:41 PMHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Diseasefinance.yahoo.com - November 13 at 6:24 PMHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstatbenzinga.com - November 10 at 1:42 PMHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstatfinance.yahoo.com - November 10 at 9:22 AMGSK Signs $1 Billion Deal for Exclusive License to J&J's Hepatitis B Therapymoney.usnews.com - October 31 at 9:19 AMHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Modelfinanznachrichten.de - October 25 at 9:35 AMHepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Modelfinance.yahoo.com - October 25 at 9:35 AMmarketbeat.com - October 13 at 2:52 PMHepion to sell $5M in shares through registered direct offeringmsn.com - September 29 at 1:23 PMHepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rulesfinance.yahoo.com - September 29 at 8:23 AMHepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conferencefinance.yahoo.com - September 21 at 5:56 PMNew Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Programfinance.yahoo.com - September 21 at 9:54 AMHere's Why Hepion Pharmaceuticals (NASDAQ:HEPA) Must Use Its Cash Wiselyfinance.yahoo.com - September 19 at 12:52 PMHepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancerfinance.yahoo.com - September 19 at 9:55 AMInsider Buying: Robert Foster Acquires 1,600 Shares of Hepion Pharmaceuticals Incfinance.yahoo.com - September 18 at 11:28 AMRencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosisfinance.yahoo.com - September 14 at 9:29 AMHepion Pharmaceuticals' CMO Todd Hobbs resignsmsn.com - September 7 at 5:27 PMHepion Pharmaceuticals Announces Management Changesfinance.yahoo.com - September 6 at 5:37 PMWall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Betfinance.yahoo.com - September 6 at 4:30 PMHEPA - Hepion Pharmaceuticals, Inc.finance.yahoo.com - August 16 at 3:18 AMHEPA Hepion Pharmaceuticals, Inc.seekingalpha.com - July 25 at 1:45 AMHepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023finance.yahoo.com - June 15 at 6:35 PMHepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciencesfinance.yahoo.com - May 24 at 5:08 PMHere's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Daysfinance.yahoo.com - May 24 at 2:12 PMWhy Hepion Pharmaceuticals Stock Is Soaring Mondaymsn.com - May 22 at 10:54 AMHepion Skyrockets on Promising Phase 2 Data in NASHmsn.com - May 22 at 10:54 AM Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13. See his shocking evidence in this new report HEPA Media Mentions By Week HEPA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HEPA News Sentiment▼-0.020.44▲Average Medical News Sentiment HEPA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HEPA Articles This Week▼111▲HEPA Articles Average Week Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LGVN News MTEM News ADIL News VIRI News CYCN News AKTX News BFRI News GRTX News TFFP News AEZS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HEPA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
